Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UKALL14 randomized trial for adults with newly diagnosed acute lymphoblastic leukemia
2009-012717-22Phase 3Unknown
- Sponsor
- University College London
- Start
- Mar 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab and pegaspargase in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by University College London. Primary endpoint: Event-free survival. Status: unknown.
02
Drugs
rituximabpegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2009-012717-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012717-22.